Icotrokinra psoriasis results: what the two-year follow-up adds

Johnson & Johnson reported on October 2 that skin-clearance responses with icotrokinra, the oral peptide sold as Icotyde, were maintained through week 112 in a study focused on psoriasis of the scalp, genitals, hands or feet.[6] The update adds longer follow-up for an already approved medicine, after the trial's comparison with placebo ended at week 16.[7][10]

Reader offer · IQON Labs

Buy 1, Get 1 Free

Pick any research compound. The second one is on us.

FREE

Applied automatically at checkout, no code needed

Claim my free vial →

Lower priced item free; accessories excluded. For research use only.

IQON Labs' research use only catalog is separate from the clinical study reported here.

Where psoriasis sits matters

A measure of how much skin psoriasis covers can miss how much it disrupts someone's life. The National Psoriasis Foundation describes worse quality of life and reduced participation in social activities when psoriasis affects certain sensitive or visible areas, independently of the total body surface area involved.[8]

That is the reason for the focus of ICONIC-TOTAL, the Phase 3 trial behind the new announcement. It enrolled 311 people aged 12 or older with at least moderate psoriasis of the scalp, genitals, hands or feet. Participants could have more than one of these sites affected, and investigators assessed both their overall skin disease and the individual sites.[7][12]

The study allowed people whose psoriasis covered as little as 1% of their body surface area, provided they met its other disease criteria. All had an inadequate response to at least one topical treatment.[12] The question was whether an oral medicine could control disease in places where the area affected alone might understate its burden.

What the oral peptide blocks

Icotrokinra acts on the receptor for interleukin-23, usually shortened to IL-23. This immune signal helps drive the inflammatory response in plaque psoriasis. The receptor is the part of the signaling system that icotrokinra blocks.[6][12]

Some established injectable psoriasis medicines target IL-23 itself. Icotrokinra instead targets the receptor that receives the signal, and does so as an oral tablet.[10][12] That gives researchers another way to intervene in the same inflammatory pathway. The trial tests whether it produces a useful effect on the skin.

The FDA approved Icotyde on March 17, 2026 for moderate to severe plaque psoriasis in adults and pediatric patients aged 12 or older who weigh at least 40 kilograms and are candidates for systemic therapy or phototherapy.[10] Systemic therapy acts throughout the body; phototherapy uses light to treat the skin. The October announcement is a follow-up result for that medicine, not a new approval.

The randomized trial's starting point

For the initial 16 weeks, 208 participants were assigned to icotrokinra and 103 to placebo in a double-blind trial, meaning participants and investigators did not know which treatment had been assigned.[7][12]

At week 16, 118 of 208 participants receiving icotrokinra, or 56.7%, met the overall skin endpoint, compared with 6 of 103 receiving placebo, or 5.8%.[12] Success required skin rated clear or minimal on the Investigator's Global Assessment, plus an improvement of at least two points from the starting score.[12]

This was a substantial separation: the study's adjusted difference was 51.1 percentage points, with a 95% confidence interval from 42.1 to 58.8 percentage points.[12] The interval describes the uncertainty around the estimated difference between the groups, rather than the range of improvement for individual patients.

The results were not equally conclusive at every site. The week 16 comparisons favored icotrokinra for scalp and genital psoriasis, while the hand and foot comparison did not reach statistical significance.[12] That hand and foot analysis involved 48 participants assigned to icotrokinra and 23 assigned to placebo; its smaller population leaves a less precise estimate than the overall trial.[12]

A "clear or almost clear" result includes people with a small amount of remaining disease. Complete clearance is a stricter result, scored as zero on the relevant assessment.[6][12]

What week 112 can tell us

After week 16, participants in the placebo group switched to icotrokinra.[7] From then on, the study followed people receiving the active medicine rather than maintaining an untreated comparison group.

J&J's October 2 announcement says skin-clearance responses were maintained through week 112 and reports complete clearance at individual body sites among some participants. The company described the results as a presentation at the European Academy of Dermatology and Venereology Congress.[6]

For a chronic disease, seeing responses well beyond the first few months addresses an important question left by the original trial. But the later observations answer a different question from the randomized phase: how people fare during continued treatment, rather than how treatment compares with placebo at the same late time point.[6][7]

These are group results at particular visits. They leave a further question about individual experience: whether a participant's skin stayed clear throughout follow-up or improved and worsened between assessments.

Safety, and why J&J is emphasizing these results

During the original 16-week assessment, adverse events occurred in 104 of the 208 icotrokinra participants, or 50.0%, and 43 of the 103 placebo participants, or 41.7%.[12] These are events recorded during treatment, not a count of events all proven to have been caused by the medicine.

For follow-up through week 112, J&J reported no new safety signals.[6] That means the company did not identify a new pattern of concern in its analysis, not that the medicine has no side effects. The FDA lists headache, nausea, cough, fungal infection and fatigue among the most common side effects; the product's safety information also warns about infection risk.[6][10]

J&J sponsored ICONIC-TOTAL and holds worldwide development and commercialization rights under its collaboration with Protagonist.[6][12] Its October announcement explicitly argues for Icotyde as a first systemic treatment option. Longer follow-up in troublesome body sites helps that commercial case, but ICONIC-TOTAL did not compare two years of icotrokinra with another active psoriasis medicine.[6][7]

The registry plans active treatment through week 156.[7] As follow-up lengthens, the useful detail will be who remains in the study, how their disease changes between visits and how missed assessments are handled. That is what will help turn a late skin-clearance headline into a fuller account of living with psoriasis during continued treatment.